Article info
Therapeutics
Randomised controlled trial
Telaprevir triple combination therapy, and dual peginterferon α-2a/ribavirin therapy for 24 weeks for those with rapid-early response is not inferior to 48 weeks of therapy for treatment-naïve patients with genotype 1 hepatitis C virus infection
- Correspondence to Mark Danta
Department of Medicine, UNSW, Level 5 deLacy Building, Darlinghurst, Sydney, NSW 2016, Australia; m.danta{at}unsw.edu.au
Citation
Telaprevir triple combination therapy, and dual peginterferon α-2a/ribavirin therapy for 24 weeks for those with rapid-early response is not inferior to 48 weeks of therapy for treatment-naïve patients with genotype 1 hepatitis C virus infection
Publication history
- First published January 31, 2012.
Online issue publication
April 09, 2020
Article Versions
- Previous version (9 April 2020).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions